Gene Tx Shows Sustained Bleeding Control in Severe Hemophilia A at 2 Years Model predicts valoctocogene roxaparvovec could maintain mild hemophilia levels for 5 years Feb 23, 2023
New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia A Weekly dosing with efanesoctocog alfa reduced annualized bleeding rate by 77% Jan 25, 2023
FDA OKs First Gene Therapy for Hemophilia B Hemgenix reduced rate of annual bleeds, eliminated need for factor IX prophylaxis therapy Nov 22, 2022
Year in Review: Hemophilia Gene therapy continues to show promise in clinical trials, but is it ready for the clinic? Nov 17, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
Lessons From a Lifelong Patient Turned Oncologist Eric Winer, MD, talks about how growing up with hemophilia helped him connect with patients Aug 02, 2022 podcast
Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
Liver Toxicity in Gene Therapy Trials Could Merit Stricter Entry Criteria FDA panel weighs in on lower vector doses and role of animal studies Sep 03, 2021
Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
Gene Therapy Stops Bleeding in Hemophilia Single injection had durable effectiveness, study showed Dec 08, 2020
Severe Nosebleeds More Common With Hypertension Korean study supports link between hypertension and epistaxis Sep 10, 2020
MSK Cancer Alliance: Mainly About Medicine Bi-directional relationship strengthens regional cancer care Mar 11, 2017
Combo Boosts PFS in Tough-to-Treat Myeloma Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone Jun 07, 2016
